Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wise shares head south as cross-border take rates fall

(Sharecast News) - Wise shares were in the red early on Thursday after revealing that its cross-border take rate fell by 12 basis points year-on-year. Wise said its cross-border volume had grown 24% year-on-year to £41.2bn in Q1, while customer holdings rose 31% to £22.9bn and total customer numbers increased by 17% to 9.8m. Underlying income was up 11% at £362m.

However, Wise said its cross-border take rate reduced by one basis point in the quarter, or 12bps in the year to 30 June, dropping to 52bps, reflecting a reduction in average prices and a continued increase in the proportion of higher volume customers in the period.

Wise also posted a 24% rise in quarterly cross-border volume to £41.2bn in the three months to end June, while customer holdings grew by 31 per cent to £22.9bn. The firm said its active customer base rose 17 per cent to 9.8m.

Looking forward, Wise said it remains focused on long-term growth opportunities and becoming "the" network for the world's money as it shifts in primary listing from Lonndon to New York.

As of 0835 BST, Wise shares were 8.30% lower at 1,038.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.